Wetherspoon ( J.d.) Share Discussion Threads

[guitarhaggis] 09/11/2020 18:22

Gozzie- So go on then, from the couple of weeks I've been on here tell me in what way I'm supposed to be 'selfish'.

[gozzie2] 09/11/2020 18:19

Unbelievable They said they nearly full and we haven't reached the peak yet .Go and do a shift there they need volunteers. On second thoughts they need sensible people lol .

[gozzie2] 09/11/2020 18:13

@rseh0le .

[gozzie2] 09/11/2020 18:12

Was just watching the BBC news about a hospital and just realised what selfish b@stards are on this board .

[guitarhaggis] 09/11/2020 18:08

Awh bless Gozzie swallowing all the fairytail stuff his uncle Boris tells him. He's such a simple little fellow.

[gozzie2] 09/11/2020 17:47

Ah Boris says you are not having the vaccine just for yourself but to protect others that are at risk Guitar .But your sort dont care about others .He hopes people wont listen to those types of arguments. You selfish lot wont listen .

[gozzie2] 09/11/2020 16:58

You must be against medicine of any kind guitar.You call the health service sc#m .You must be a very healthy chap .Why don't we go back to the 1600s they was much healthier without vaccine. You was lucky if you made it past 2 years of age .

[rescuer] 09/11/2020 16:08

here comes the mkt pull back, what a corrupt, manipulative mkt we have.

rolls royce up just short of 100% earlier, now only up 50%,

un-tradable mkts today - technicals out the window - support and resistance blown away.

think i'll sit the rest of the week out, apart from Wednesday when it's JDW update day.

hope you're all still hanging in - if you're Longs - well done folks, remember to take profit.

[guitarhaggis] 09/11/2020 15:50

Luderitz- They can't have it 100% effective otherwise they wouldn't be able to make billions every year from people like Gozzie queuing round the block for an update like he does every autumn outside Game waiting to pick up the latest version of FIFA for his Playstation. It was always going to 'need' endless jabs.

[gozzie2] 09/11/2020 15:40

Dr Campbell on you tube hes very good .

[gozzie2] 09/11/2020 15:39

That mink story that my friend is not interested in could turn out to be a big story .The doc points out we don't know yet but my friend is not bothered in the slightest .Just guesses and gets information from dubious sources as do many lol .My brothers the same I wonder which one I will correct him on this week lol .

[gozzie2] 09/11/2020 15:35

Err because the govt are asking you to and will be promoting it .

[luderitz] 09/11/2020 15:35

Copenhagen in Denmark has warned that the mutation could threaten the effectiveness of any future vaccine... that's "any" future vaccine!

[guitarhaggis] 09/11/2020 15:27

Gozzie- It's perfectly logical. Why should the taxpayer pick up the bill if you volunteer to take a vaccine that hasn't been proven to be safe medium to long term?

[gozzie2] 09/11/2020 15:22

You have strange logic lol .

[guitarhaggis] 09/11/2020 15:10

Gozzie- I think if anybody wants to take the vaccine then great but using your argument if they fall ill or suffer any side effects of taking it then they should not be allowed NHS treatment or be of any burden to the taxpayer.

[gozzie2] 09/11/2020 15:04

Go for it then most likely 200,000 deaths all around the same time like I've said .Just suffer and if it gets that bad, get the neighbours to put a pillow over your head .You won't be getting an ambulance. It will cut down on the pensions at least. Not a bad idea the tories will be finished. In fact I'm coming round to your way of thinking .

[guitarhaggis] 09/11/2020 14:57

Gozzie- Hence herd immunity, making these vaccines unnecessary.

[qantas] 09/11/2020 14:57

John is just a short hit with a sledgehammer today.

[gozzie2] 09/11/2020 14:45

I told you we are wasting our time these Trump supporters won't take it around 50 percent .Vaccine promoters say they need to start now to counter all this, because epidemiologists estimate that to break the pandemic, 70% of the population may need to develop immunity, either by getting a vaccine or becoming infected. 

[johnwise] 09/11/2020 14:38

Ill pass, just give mine to a sheep

Anybody who takes a vaccine that has been developed in 8 months has something wrong with their head. The 1976 swine flu vaccine in the US was rushed out with disastrous consequences and the 2010 swine flu vaccine was not a lot better.

Vaccine Damage Payment - GOV.UK

[gozzie2] 09/11/2020 14:13

I think its a little over the top the optimism also reading into it .

[rescuer] 09/11/2020 14:09

again, sensationalist headlines with no backup story - mkt manipulation at it's best.

the vaccine needs to be kept at Minus 80 degrees, you need two jabs within 3 weeks and they don't know the longer term results.

whilst i may have taken a bit of a kick here this morning, plsd i'm not in any Pharmas, they are being trashed.

hope you all have faired well over the past few hours.

[gozzie2] 09/11/2020 14:08

Watershed moment and 'cautiously optimistic' - Scientists and academics react to news of Pfizer vaccine breakthroughProf Eleanor Riley, Professor of Immunology and Infectious Disease, University of Edinburgh"At face value, this is exceptionally good news: a vaccine that is 90% effective at preventing symptomatic cases of COVID-19 and with millions of doses available by the end of the year. However, the full data set on which the claim is based has not yet been released and so we don't know exactly what has been found. The two companies are at pains to point out that the trial participants are ethnically diverse, which is good, but say nothing about the age of people in the trial. If a vaccine is to reduce severe disease and death, and thus enable the population at large to return to their normal day-to-day lives, it will need to be effective in older and elderly members of our society. We also know nothing yet about the severity of cases that were seen in the trial, whether infection or infectiousness was prevented, or how long the immunity is expected to last. But, I think we have reason to be cautiously optimistic."Prof Peter Horby, Professor of Emerging Infectious Diseases and Global Health in the Nuffield Department of Medicine, University of Oxford"This news made me smile from ear to ear. It is a relief to see such positive results on this vaccine and bodes well for COVID-19 vaccines in general. Of course we need to see more detail and await the final results, and there is a long, long way to go before vaccines will start to make a real difference, but this feels to me like a watershed moment."Prof Brendan Wren, Professor of Microbial Pathogenesis, London School of Hygiene & Tropical Medicine"A 90% efficacy for a phase 3 trial is excellent for a new vaccine that could make a huge difference, but more confirmatory safety and efficacy studies are required. The RNA-based vaccine requires two doses and its true efficacy over a longer period of time remains to be evaluated. These are encouraging results and it is a case of so far so good."Prof Lawrence Young, Professor of Molecular Oncology, Warwick Medical School"This is a very timely and encouraging development in the race to get an effective vaccine. It is difficult to fully evaluate the interim data without more information but it appears that the vaccine is able to protect against COVID-19 disease. The big question is whether the vaccine can block virus infection and subsequent transmission. This additional data will be generated as further confirmed cases are identified and analysed. This trial is using a mRNA-based vaccine containing the SARS-CoV-2 spike protein combined with a lipid nanoparticle. Almost all of the other vaccines using different technology platforms are focusing on the same virus spike protein. So it is likely that some of these other vaccines will also be able to prevent COVID-19.  The challenge with the distribution of the Pfizer vaccine is the need to store and maintain the vaccine at very low temperatures (-70 to -80 degrees C)."Dr Michael Head, Senior Research Fellow in Global Health, University of Southampton"This cautiously sounds like an excellent result from the phase 3 trials, but we should remain a little cautious. The provisional findings are made available in a press release, and the study is ongoing. However, if the final results show an effectiveness of anywhere near 90% with response in elderly and ethnic minority populations, that is an excellent result for a first generation vaccine. This has been seen before – the rapidly-produced Ebola vaccine generated very high levels of effectiveness and exceeded all expectations. Equally, billions of dollars and numerous clinical trials have struggled to produce any form of vaccination against HIV. Science can be unpredictable. If this Pfizer vaccine candidate is licensed, there will be difficulties around logistics and distribution.  It has been reported that the vaccine requires storage at -70 degrees centigrade, and that is not necessarily routinely available in most health centres even in the UK, let alone globally."Prof Azra Ghani, Chair in Infectious Disease Epidemiology, Imperial College London"These new results represent the first demonstration of substantial efficacy of a vaccine candidate against COVID-19 disease which is very welcome news. It is important to bear in mind that these are early results based on a relatively small number of cases. In addition, the efficacy estimate is based on seven days of follow-up of participants following the second dose; further data in the coming weeks and months will provide a better picture of longer-term vaccine efficacy."Prof Ian Jones, Professor of Virology, University of Reading"Of all the current vaccines currently in development the BioNtech product always looked like the most bang-per-buck as it is entirely focused on the part of the virus that binds to the human cell, the receptor binding domain. The questions around its use were about the ability to manufacture at scale and the possible toxicity associated with a directly injected RNA product. The trial data shows excellent results in both of those areas, really impressive protection and no reported adverse events. The only things we will not know for some time is the longevity of the response in all age groups, but assuming antibody titres are high that should be at least as good as any other vaccine currently in trial. More generally this would appear to indicate that this approach has legs and is likely to useful for other emerging disease."13:32?Vaccine breakthrough: What we knowThe UK government has secured around 30 million doses of the potential vaccine - enough for 15 million people - in an agreement with the two firms behind itThe coronavirus vaccine is being developed by US pharmaceutical giant Pfizer and German biotech firm BioNTechIt has been found to be 90% effective in preventing people from getting the virusIt is one of around 12 worldwide in the final stages of testing, but it is the first to produce any resultsThe firms say they can supply 50 million doses by the end of 2020 and 1.3 billion by the end of 2021Today's findings follow interim analysis of the vaccine's phase 3 trialsAround 43,538 participants from six countries took part in the third stage of the clinical trialsThey received two doses of either the immunisation or a placeboAnalysis suggests 90% of those involved were protected from the virus within 28 days of having their jabsOnly 94 people who took part in the trials developed coronavirus and no serious safety concerns were reported13:20?Analysis: Pfizer vaccine breakthrough an extraordinary resultBy Thomas Moore, science correspondentFew scientists would have expected a first-wave COVID vaccine to be 90% effective.Many had said that a jab that prevented just 50% of cases would be a game-changer.So, with almost 1.3 million deaths so far in the pandemic, you can understand why the boss of Pfizer has called this "a great day for science and humanity".If the results are as good in high risk elderly patients – and we don't know that for sure until the company has done more analysis – it would mean the vaccine would prevent 90% of hospital admissions and deaths.The result comes from the phase 3 clinical trials, in which more than 43,000 volunteers have been given either the vaccine, currently code-named BNT162b2, or a placebo.By comparing the number of COVID cases in each group, the company was able to work out the protection given by the vaccine.It's important to stress that this is the level of protection just after the second dose. The trials haven't been going for long enough to tell whether the protection will wane, or by how much.Nor do we yet know whether the vaccine stops the virus transmitting. If not, then there may still need to be some degree of social distancing. We would still be living with the virus.Nevertheless this is an extraordinary result for Pfizer and BioNTech, the German biotech company that it has been collaborating with.The vaccine uses technology that has never reached clinical use.It contains a short strand of mRNA, the coding information that makes a tiny portion of one part the coronavirus, rather than the more traditional method of inactivating the whole virus.It should mean the vaccine is quicker to make at scale. That's yet to be tested of course.If further analysis of trial data later this month confirms the vaccine has no major side effects the company will file for Emergency Use Authorisation and it will be rolled out as fast as possible.The UK has a deal for 30 million doses, enough for 15 million people, with priority being given to those most at risk.The vaccine being developed by Oxford University and AstraZeneca is also expected to report key data this month on whether it works.Dare we hope for a similarly good result?We're in the closing stages of the race for a vaccine. And it looks like at least one of the runners was a thoroughbred.12:54Coronavirus vaccine hopes spark global stock market surgeThe FTSE 100 has rallied sharply on growing hopes of a coronavirus vaccine - building on gains in reaction to Joe Biden's US election victory.The index was more than 5% higher in early afternoon deals after US drug firm Pfizer revealed that early data from phase three trials showed its vaccine was 90% effective against COVID-19.It followed overnight gains in Asia, with Japan's Nikkei hitting a 29-year high after the confirmation of the US election result over the weekend which also bolstered values across Europe.The FTSE had been 1.7% up in early trading while indices in France and Germany saw similar increases.The CAC in Paris and Frankfurt's DAX were also more than 5% higher and US futures indicated the S&P 500 would leap by more than 3.5% at the open, in reaction to the vaccine developments.The update on the Pfizer-BioNTech trial raises hopes that economic damage from the coronavirus crisis can be limited if populations can be widely protected. Read more here.12:46Boris Johnson to hold COVID news briefing laterPrime Minister Boris Johnson will give a news briefing from Downing Street at 5pm.The PM will be joined by deputy chief medical officer Professor Jonathan Van-Tam and Brigadier Joe Fossey at the Downing Street press conference, No 10 said.Updates on the mass testing pilot in Liverpool are expected.It comes after pharmaceutical firms Pfizer and BioNtech announced early analysis of phase 3 trials of their potential coronavirus vaccine suggests it is 90% effective against COVID-19.12:36Pfizer and BioNTech potential vaccine breakthrough 'should give us tentative hope', says Nicola SturgeonFirst Minister of Scotland Nicola Sturgeon has welcomed the news of the Pfizer and BioNTech potential vaccine breakthrough."There is a long way to go but this is news that should give us tentative hope," she says.12:29'Some tentative positive early signs' give us hope of firebreak lockdown impact - First Minister of WalesFirst Minister of Wales Mark Drakeford says the country's exit from the firebreak lockdown "needs to be careful and cautious so we can maximise its impact".He tells a news conference in Cardiff that COVID-19 is "full of unpleasant surprises" following the discovery of a new mutated strain of coronavirus in mink in Denmark."We won't know the full impact of our firebreak for a few weeks yet," he says, adding: "But there are some tentative positive early signs and those give us some hope."Mobility data shows large increases in people staying at home during the firebreak, similar to levels seen in May."It is vital that working from home continues beyond today."The firebreak lockdown has ended, but a new set of national measures in Wales are in place, which Mr Drakeford says will be reviewed in two weeks.12:07Pharmaceutical giant and biotech firm say analysis suggests their potential vaccine is 'more than 90% effective' against COVID-19The coronavirus vaccine being developed by Pfizer and BioNTech has been found to be 90% effective in preventing people from getting the virus, it has been confirmed.Phase 3 of Pfizer's trial involved 43,538 participants. They received two doses of either the immunisation or a placebo, with 90% protected from the virus within 28 days of having their jabs.Only 94 people who took part in the trial developed coronavirus and no serious safety concerns were reported."Today is a great day for science and humanity. The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine's ability to prevent COVID-19," said Pfizer chairman and chief executive Dr Albert Bourla."With today's news, we are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis.""The first interim analysis of our global phase 3 study provides evidence that a vaccine may effectively prevent COVID-19. This is a victory for innovation, science and a global collaborative effort," added Professor Ugur Sahin, BioNTech co-founder and CEO.Pfizer and BioNTech's vaccine is one of many being developed around the world in the race to end the global pandemic.The pharmaceutical giant says it can supply 50 million doses by the end of 2020 and 1.3 billion by the end of 2021.